Fake Ozempic Seized by FDA: Patient Safety at Risk

The U.S. Food and Drug Administration (FDA) issued a warning on Thursday, stating that numerous units of counterfeit Ozempic have been seized. While the agency continues to investigate, it cautions that some fraudulent units of the diabetes drug, produced by Novo Nordisk, may still be circulating in the market.

To determine the quality and safety of the seized products, both Novo Nordisk and the FDA are conducting tests. It is important to note that these counterfeit products also feature counterfeit needles, which pose a serious risk of infection due to the inability to confirm their sterility.

Patients are strongly advised to examine all received products and cross-reference the lot and serial numbers listed on the FDA's website with those associated with the counterfeit products.

Regrettably, at least five adverse events have been reported in connection with these counterfeit products. These incidents align with typical side effects of genuine Ozempic, such as nausea and vomiting.

In response to this concerning issue, Novo Nordisk released a statement expressing their dedication to combatting counterfeit products and unlawful activities within the market. They have vowed to collaborate with the FDA in order to identify any potential imitation products in the United States.

Patient safety remains of utmost importance, and both the FDA and Novo Nordisk are taking swift action to address this critical situation.